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Background: T cells are important to systemic lupus erythematosus (SLE) disease progression. This study
determined the pro-inflammatory potential of T cells within the rare condition juvenile-onset SLE (JSLE).
Method: IL-17A and Th1/Th2-related cytokine concentrations were measured in plasma/serum from JSLE patients
(n = 19, n = 11) and HC (n = 18, n = 7). IL17A, RORC, IL23 and IL23R mRNA were measured in peripheral blood
mononuclear cells (PBMCs) from JSLE and healthy controls (HC) (n = 12). Th17-associated cytokine expression was
analysed in the supernatant of CD3/CD28 activated JSLE (n = 7) and HC (n = 6) PBMCs.
Results: JSLE plasma IL-17A level (21.5 ± 5.2 pg/ml) was higher compared to HC (7.2 ± 2.5 pg/ml, p = 0.028). No
differences were found in Th1/Th2 cytokines levels. IL = 17A (p = 0.022), IL-6 (p = 0.028) and IL-21 (p = 0.003)
concentrations were increased in supernatants from activated JSLE PBMCs. IL-17 F (p = 0.50) and IL-22 (p = 0.43)
were also increased but were not statistically significant. IL17A and IL23 mRNA was significantly higher in JSLE
PBMCs (p = 0.018 and p = 0.01).
Conclusion: JSLE T cells have an increased ability to secrete Th17 associated cytokines once activated, which could
contribute to the pro-inflammatory disease phenotype seen in these patients.
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The autoimmune disease Systemic Lupus Erythematosus
(SLE) is characterised by chronic inflammation, autoanti-
body production and severe organ damage. Juvenile-onset
SLE (JSLE) is less common than adult onset disease affec-
ting between 6 and 30 people per 100,000 depending on
ethic group [1]. JSLE manifests before 17 years of age, pre-
sents with significantly more active disease, and is associ-
ated with greater tissue damage and increased patient
mortality in comparison to adult-onset lupus [2]. There is
no cure and most treatments focus on reducing tissue in-
flammation. Better understanding of the inflammatory
pathways resulting in JSLE is essential for the develop-
ment of improved treatment strategies for these patient
groups.
Evidence, primarily from studies of adult-onset disease,
indicates SLE development is characterised by a critical* Correspondence: lucy_b12@hotmail.com
1Department of Women’s and Children’s Health, Institute of Translational
Medicine, University of Liverpool, Alder Hey Children’s NHS Foundation Trust
Hospital Eaton Road, Liverpool L12 2AP, UK
Full list of author information is available at the end of the article
© 2014 Ballantine et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.imbalance in T lymphocyte homeostasis, resulting in dys-
regulated or abnormal cytokine expression and autoanti-
body production [3-6]. The main T cell subsets which are
central for T cell homeostasis are CD4+ T helper (Th) cells
and regulatory T cells (Tregs) [7].
Within SLE, CD4+ T cells are known to regulate B
cell autoantibody production through provision of co-
stimulatory signals and cytokines [8]. However the role
of individual T cell subsets in JSLE whilst central to dis-
ease progression remains poorly defined. Early studies of
adult-onset SLE hypothesised a single CD4+ T cell subset
was a key mediator of disease [3,9], focussing on the T
helper (Th) 1 or Th2 subtypes characterised by ex-
pression of interferon gamma (IFNɣ) or Interleukin (IL)
4 respectively. More recently the identification of Th17
cells characterised by the production of IL-17A, IL-17 F,
IL-21 and IL-22 and the expression of the IL-23 receptor
(IL-23R) has led to the suggestion of other T cell subsets
contributing to disease progression. Alternatively, an im-
balance of T cell subsets which cross regulate each other
or disproportionate Th17-to-Treg ratio may contributeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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disease [4-6,10-13]. The pathogenesis of juvenile-onset
lupus may depend on the predominance of specific ef-
fector T-cell subsets leading to tissue inflammation. This
study aimed to analyse the pro-inflammatory potential of
T cell populations, particularly with regard to Th17 cells.
Methods
Patients and controls
The Liverpool Paediatric Research Ethics Committee
approved this study. Written informed consent was ob-
tained from all participating subjects or their parent/
guardian. JSLE patients fulfilled the revised American
College of Rheumatology (ACR) criteria for the diag-
nosis of SLE [14] before the age of 17 years. Paediatric
non-inflammatory controls were children without inter-
current infection or non-inflammatory musculoskeletal
symptoms and had undergone elective surgery. All pae-
diatric patients were recruited at Alder Hey Children’s
National Health Service (NHS) Foundation Trust. JSLE
disease activity data was collected using a paediatric adap-
tation of the British Isles Lupus Assessment Group
(BILAG) 2004 (pBILAG2004) disease activity score [15].
Cell preparation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from fresh heparinised blood within 1 hour of col-
lection by 1-step centrifugation through Polymorph Prep
(Axis-shield, UK) following manufacturer’s instructions.
CD3/CD28 PBMC activation and measurement of
cytokines
PBMCs were re-suspended at a concentration of 1 × 106
cells/ml in RPMI 1640 medium (Sigma-Aldrich) supple-
mented with 10% fetal calf serum (Sigma-Aldrich) and
1% penicillin/Streptomycin (Sigma-Aldrich). PBMCs were
seeded into a 96 well culture plate (Nunc) at 5 × 105/well
in triplicate and stimulated with beads coated with anti-
bodies to CD3/CD28 (2.5 × 105 beads/well; Miltenyi Bio-
tech) producing a final bead-to-cell ratio of 1:2. The
PBMC were incubated at 37°C in an atmosphere contain-
ing 5% CO2. After 2 days cell free supernatants were col-
lected and the concentration of IL-17A in supernatants
was assessed using an enzyme-linked immunosorbant
assay (ELISA) kit according to the manufacturer’s instruc-
tions (ebioscience, San Diego, US), the detection limit was
7.8 pg/ml.
Measurement of cytokine concentrations
IL-17A concentration in plasma samples was mea-
sured using a commercially available Human IL-17A
Immunoassay Quantikine® ELISA kit (R + D Systems
Inc., Minneapolis, MN, USA) following manufacturer’s
instructions.Levels of IL-6, IL-21, IL-22 and IL-17 F in cell culture
supernatant were measured using Bio-plex Pro Human
Th17 cytokine assay and levels of IL-12, IFNγ, IL-4 and
IL-13 were measured in serum samples using a Bio-Plex
Pro Human Cytokine 27-Plex Panel (Bio-Rad Laboratories)
following the manufacturer’s instructions.
mRNA preparation and qRT-PCR
RNA was extracted from PBMCs using the RNeasy Mini
kit (Qiagen Inc.). The concentration and purity of RNA
was confirmed by the relative absorbance at 260 nm
and measuring the 260/280 nm ratio using an ND-1000
NanoDrop spectrometer (Thermo Scientific). First strand
cDNA synthesis was initiated from 100 ng total RNA
using random hexamers (Promega) and avian myeloblas-
tosis virus reverse transcriptase (Promega) using condi-
tions described by the manufacturer in a final volume of
25 μl. The primers used were as follows: IL17A forward 5′
GAA TCT CCA CCG CAA TGA GGA CCC 3′; reverse
5′ GTT GAT GCA GCC CAA GTG GCG 3′; RORC for-
ward 5′ GTC CCG AGA TGC TGT CAA GT 3′; reverse
5′ TGA GGG TAT CTG CTC CTT GG 3′; IL23R for-
ward 5′ ACA GGG CAC CTTACT TCT GAC AA 3′; re-
verse 5′ AGC AAA GAC GAT CAT TCC CAAT 3′; IL23
forward 5′ AGA GGG CAC CTT ACT TCT GAC AA 3′;
reverse 5′ AGC AAA GAC GAT CAT TCC CAA T 3′;
RPL13A forward 5′ TTT CCA AGC GGC TGA CGA AG
3′; reverse 5′ AGC AAA GAC GAT CAT TCC CAA T
3′. All quantitative real-time PCR took place using the
SYBR green fluorescence method with SYBR green qPCR
mastermix (Stratagene) as specified by the manufacturer.
Real-time PCR reactions took place in triplicate on a
MX4000® Multiplex Quantitative QPCR system (Strata-
gene) using standard thermal cycling conditions. Non-
template controls were prepared by replacing the cDNA
fraction of the PCR reaction with an equivalent volume of
nuclease free water (Promega). RPL13A was monitored as
an internal standard for the PBMCs. mRNA expression
for each gene was normalised to these internal standards.
Absolute quantification was obtained using the standard
curve method of analysis.
Statistical analysis
All data are presented as the mean ± SEM. Comparisons
between JSLE and control patients were made using the
Mann–Whitney test. All analyses were performed using
GraphPad Prism 4 software (Graph Pad Software, San
Diego, CA). p < 0.05 were considered significant.
Results
Clinical characteristics of patients
Thirty JSLE patients were studied; Table 1 presents data
for the demographic, clinical biomarker of disease ac-
tivity, physician’s global assessment of disease activity,
Table 1 Juvenile-onset SLE patient data
Demographics Juvenile-onset SLE
patients (n = 30)





Age at sampling, mean (range) years 12.4 (3.4 – 17.9)
Disease duration, mean (range) years 2.9 (0.01 – 10.2)
Biomarker/disease activity parameter,
mean (range)
ESR, mm/hour (normal 2 – 8 mm/hour) 9.3 (<1 – 60)
CRP, mg/litre (normal 0 – 8 mg/litre) 6.8 (<4 – 78)
C3, gm/litre (normal 1.1 – 1.9) 1.03 (0.4 – 1.37)
C4, gm/litre (normal 0.19 – 0.56) 0.20 (0.08 – 0.46)
Anti-dsDNA titre, IU/ml (normal <7) 7.6 (0 – 96)
C-HAQ score, 0–3, mean (range) 0.32 (0 – 1.5)
Physician’s global assessment of disease activity
by VAS, mean (range) mm
20 (0 – 75)
SLEDAI score, mean (range) 4.4 (0 – 17)
BILAG-2004
Number with grade A or grade B 9
Score, mean (range) 2.03 (0 – 8)






Prednisolone dosage, mean (range) mg/day 12.2 (1 – 40)
Rituximab 4
Data on demographics, biomarker parameters, pBILAG2004 disease activity
scores, and current medications in patients with juvenile-onset SLE.
BILAG = British Isles Lupus Assessment Group; SLE = systemic lupus
erythematosus; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein;
anti-dsDNA = anti–double-stranded DNA; C-HAQ = Childhood Health
Assessment Questionnaire; VAS = visual analog scale (0–100-mm).
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tions of the patient group. Disease activity at time of
sampling varied from mild to severe, with a range of
therapeutic modalities being used. Due to small volumes
of blood obtained from the paediatric samples, we were
unable to use the same group of JSLE patients for every
experiment. Additional file 1: Table S1–S4 describe pa-
tient subsets used in each part of this study.
Fifty-seven paediatric non-inflammatory healthy pa-
tients were included as controls mean age 13.1 years
(range 2–17 years); of which 27 were female (47%). All
were of white British ethnicity.JSLE serum and plasma has a bias toward Th17 cytokines
compared to healthy control
To determine which T helper cell phenotype are active
in vivo during ongoing JSLE disease, cytokine levels
in the blood were measured (Figure 1). JSLE patients
(n = 19) were found to have a significantly higher level of
IL-17A (21.5 ± 5.2 pg/ml) in comparison to controls
(n = 18, 7.2 ± 2.5 pg/ml, p = 0.028; Figure 1A). mRNA le-
vels of IL-17A, RORC (gene encoding Th17 transcrip-
tion factor (RORɣT), the Th17 stabilising cytokine IL-23
and its receptor IL-23R were measured in JSLE and
control PBMCs (Figure 1B). The relative expression of
IL-17A and IL-23 were both significantly higher in JSLE
PBMCs in comparison to those of healthy control pa-
tients (p = 0.018 and p = 0.010 respectively). The levels
of RORC and IL-23R were also higher in JSLE PBMCs
but did not reach statistical significance (Figure 1B).
Levels of the Th1 cytokines IL-12 and IFNγ and the Th2
cytokines IL-4 and IL-13 were not statistically significantly
increased in JSLE patients (n = 11); BILAG −2004, A/B =6
score, mean (range) (3.8 (0–12)) compared to control
(n = 7) patient serum (data not shown). These data in-
dicate that Th17 cell may be the dominant Th cell in
JSLE patients, reflected by the significantly higher
levels of IL-17A in patient plasma.
Comparison of JSLE patients who had active renal dis-
ease (pBILAG2004 score of A or B; n = 6) to those who
did not (pBILAG2004 score C-E; n = 13) demonstrated
that patients with active renal disease at the time of
sampling had higher plasma levels of IL-17A but this
difference was not significant (23.92 ± 4.5 pg/ml versus
17.46 ± 6.1 pg/ml, p = 0.16). However, it should be noted
that renal JSLE patients had statistically significantly
higher levels of IL-17A in comparison to healthy con-
trol plasma (23.92 ± 4.5 pg/ml versus 7.23 ± 2.5 pg/ml,
p = 0.005).
Increased secretion of IL-17A and Th17 related cytokines
by PBMCs from JSLE patients stimulated with CD3/CD28
activation beads
To fully characterise the production of IL-17A and Th17
related cytokines, PBMCs from JSLE (n = 7) and control
(n = 6) patients were stimulated with anti-CD3 and anti-
CD28 coated microbeads for 2 days in vitro to induce
T cell activation and supernatants were analysed by
ELISA. Levels of IL-17A secreted from PBMCs of pa-
tients with JSLE (297.8 ± 116.3 pg/ml) were signifi-
cantly higher than from control PBMCs (26.2 ± 7.3 pg.ml)
(p = 0.022) (Figure 2A).
To further measure the Th17 profile of the stimulated
cells, 9 JSLE PBMC and 10 control PBMC superna-
tants were analysed using a Th17 cytokine panel bio-
plex (Figure 2B). JSLE PBMCs secreted increased levels of
cytokines known to be produced by Th17 cells which
Figure 1 Cytokines measurement in JSLE patient plasma and serum. (A) IL-17A was measured in plasma from 19 JSLE patients (n = 19;
BILAG −2004, A/B = 10; Score, mean (range) 3.1 (0–11)) and 18 healthy controls. JSLE patient levels were significantly higher IL-17A plasma levels
compared to healthy controls p = 0.028. (B) PBMCs were isolated from JSLE (n = 12; BILAG −2004, A/B = 6; Score, mean (range) 2.9 (0–8)) and
control (n = 12) patients, all genes are expressed relative to the housekeeping gene RPL13A. IL17A, IL23R, RORC and IL23 mRNA were higher in
JSLE PBMCs compared to control with IL17A and IL23 mRNA level reaching statistical significance (p = 0.018 and p = 0.01). Data are shown as the
mean ± SEM and a Mann–Whitney U test was performed to determine significance values.
Figure 2 IL-17A and Th17 associated cytokine measurement of the cell culture supernatant from CD3/CD28 activated PBMCs.
(A) PBMCs from JSLE (n = 7) and control (n = 6) patients were stimulated for 2 days using CD3/CD28 activation beads and IL-17A levels measured
in culture supernatants. JSLE patients had a significantly increased level of IL-17A secretion (p = 0.022). (B) Cell culture supernatants from JSLE
(n = 9) and control (n = 10) stimulated PBMCs were analysed by bioplex for Th17 associated cytokines. The cytokine IL-6 which is associated with
the generation of Th17 cells from naïve T cells was increased in JSLE PBMCs compared to controls (p = 0.028). Cytokines produced by Th17 cells
such as IL-17 F (p = 0.50), IL-21 (p = 0.003) and IL-22 (p = 0.43) were also increased in JSLE PBMCs compared to controls. Data are shown as the
mean ± SEM and a Mann–Whitney U test was performed to determine significance values.
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IL-22 (Figure 2B); the level of IL-21 was statistically
significantly higher in JSLE compared to control su-
pernatants (p = 0.003). JSLE supernatants also contained
significantly increased IL-6 (p = 0.028). These results de-
monstrate that upon stimulation, JSLE PBMCs have
an increased ability to produce Th17 cytokines and IL-6
required for the further generation of Th17 cells.
Discussion and conclusions
This study analysed the pro-inflammatory potential of T
cell populations in JSLE patients. We have shown JSLE
patients have significantly increased plasma IL-17A in
comparison to healthy controls but no differences in
serum levels of Th1 or Th2 associated cytokines. Fur-
thermore, in vitro activation of JSLE PBMCs resulted
in increased IL-17A and Th17-associated cytokines
(IL-17 F, IL-21, and IL-22) in comparison to control
PBMCs and increased IL-6, which has been shown to
be involved in Th17 differentiation.
Although CD4+ T cells appear to be essential in the
development of lupus in mice and humans, it is still un-
resolved which type of Th cells plays a dominant role.
Before the identification of Th17 cells, the overproduc-
tion of Th1 and Th2 cytokines including IFN-γ and IL-4
was reported in patients with SLE [16]. However, recent
data from human and murine studies clearly implicates
IL-17 and Th17 cells in lupus pathogenesis [4,6]. Our
data show significantly elevated levels of IL-17A but not
Th1 or Th2 associated cytokines suggesting that Th17
cells are the dominant active T helper cell type within
our JSLE patients.
Previous studies have found that JSLE patients suffer
from a higher proportion of renal disease in comparison
to patients with adult-onset SLE [17]. Therefore the cir-
culating IL-17A levels in JSLE patients who had active
renal disease (pBILAG2004 score of A or B) and those
who did not (pBILAG2004 score C-E) were compared.
The six patients classed as having active renal disease at
the time of blood sampling had higher plasma levels of
IL-17A in comparison to non-active renal patients al-
though this difference was not statistically significant.
This suggests that IL-17A and Th17 cells may be more
strongly associated with renal disease in our JSLE pa-
tients and are consistent with previous studies that de-
monstrated higher levels of IL-17A within serum of
children with active renal disease [18].
Predominance of Th17 cells in JSLE was further tested
by stimulation with CD3/CD28. This has the advantage
of mimicking antigen dependant activation and allows
cells to be stimulated in vitro. Our results indicate that
only a proportion of the cells can be activated. This
could be a reflection of the disease activity of the pa-
tients as two of the patients with higher cytokine levelshad active renal disease. In addition, these results could
also reflect the environment the cells have come from,
as all of the JSLE patients analysed were on various
forms of treatment (see Additional file 1: Table S1–S4).
Medication has previously been shown to affect levels of
Th17 cells and IL-17A production in rheumatoid arth-
ritis (RA) patients [19,20].
We demonstrated increased IL-6 expression by JSLE
PBMCs following CD3/CD28 stimulation which in vivo
could support increased differentiation of Th17 cells.
Cytokines known to be produced by Th17 cells inclu-
ding IL-17A (p = 0.022), IL-17 F, IL-21 (p = 0.003) and
IL-22 were also secreted at a higher level from stimu-
lated JSLE PBMCs in comparison to control PBMCs, in-
dicating that JSLE PBMCs could be pre-programmed to
a more pathogenic phenotype. Within the disease setting
of JSLE the PBMCs may be similarly activated once they
have migrated to disease affected organs. Notably, IL-17+
infiltrating T cells have previously been detected in the
kidney’s of adult SLE patients [21] and IL-17A protein
has been found in cutaneous lesions of adult SLE pa-
tients [22].
Increased serum levels of IFN-α and the IFN-α gene
signature exhibited by JSLE patients are thought to sig-
nificantly contribute to the development and mainten-
ance of autoimmunity in JSLE, through the chronic
activation of autoreactive T and B cells [23]. The inter-
action of this pro-inflammatory cytokine with IL-17 and
the differentiation of Th cell subtypes warrants further
investigation.
In conclusion, our data show that JSLE patient T cells
have an increased ability to secrete Th-17 associated cy-
tokines once they are co-stimulated. Further character-
isation of the cells producing IL-17 in JSLE is needed.
Our data provides important information for on-going
research in this area. Studies that investigate the ability
to reduce IL-17 cell activity are essential in order to de-
sign future therapeutic strategies.Additional file
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